Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3.

Reich, K; Hansen, J B; Puig, L; Konstantinou, M P; Warren, R B

Reich, K; Hansen, J B; Puig, L; Konstantinou, M P; Warren, R B.

Affiliation

Reich K; Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Hansen JB; LEO Pharma, Ballerup, Denmark.
Puig L; Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.
Konstantinou MP; Service de Dermatologie, Larrey Hospital, Toulouse, France.
Warren RB; Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, UK.

J Eur Acad Dermatol Venereol ; 35(10): 2034-2044, 2021 Oct.

Article in En | MEDLINE | ID: mdl-34076919

Subject(s)

Psoriasis; Ustekinumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Humans; Psoriasis/drug therapy; Severity of Illness Index; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Psoriasis / Ustekinumab Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Year: 2021 Type: Article

Fulltext

XML

PubMed Links

Search on Google